NanoString Technologies to Present at the JP Morgan 32nd Annual Healthcare Conference Print
GlobeNewswire
Monday, 06 January 2014 10:05

SEATTLE--NanoString Technologies, Inc. (Nasdaq:NSTG) today announced that its management is scheduled to participate in the JP Morgan 32nd Annual Healthcare Conference on January 15, 2014 in San Francisco.

NanoString management is scheduled to present at 4:00pm PT/ 7:00 pm ET. Interested parties can access the live audio webcast for this conference presentation at www.nanostring.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the nCounter Dx Analysis System. The company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. The company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic assay to be marketed through the company's diagnostics business.

For more information, please visit www.nanostring.com.

The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.

CONTACT: Investor Contact:          Lynn Pieper of Westwicke Partners          For NanoString Technologies          lynn.pieper@westwicke.com          415-202-5678                    Media Contact:          Nicole Litchfield          For NanoString Technologies          nicole@bioscribe.com          415-793-6468



BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and
investor relation services from various entities and

Error. Page cannot be displayed. Please contact your service provider for more details. (20)

firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1